LUNGevityHunter Posted December 3, 2021 Share Posted December 3, 2021 Visit https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT04938817 or call 888-577-8839 for more information KEYNOTE-B98 - Safety and efficacy study of Pembrolizumab in combination with investigational agents for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in need of second-line therapy. (NCT04938817) You may be able to join this study if your ES-SCLC has gotten worse. ES-SCLC is a type of advanced SCLC that has spread to other parts of the body. The trial drug you get will depend on which group you are placed in. This trial has 4 groups: Group 1 will get MK-1308A. Group 2 will get MK-1308A and lenvatinib. Group 3 will get MK-1308A and MK-4830. Group 4 will get coformulation favezelimab/pembrolizumab. You, your trial doctor, and the trial staff will know what you are getting. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.